Published in J Virol on May 01, 1998
Foot-and-mouth disease. Clin Microbiol Rev (2004) 4.34
Bioinformatics in new generation flavivirus vaccines. J Biomed Biotechnol (2010) 0.81
Increasing a robust antigen-specific cytotoxic T lymphocyte response by FMDV DNA vaccination with IL-9 expressing construct. J Biomed Biotechnol (2010) 0.79
Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles. Int J Nanomedicine (2014) 0.78
Recombinant DNA and Protein Vaccines for Foot-and-mouth Disease Induce Humoral and Cellular Immune Responses in Mice. Immune Netw (2009) 0.78
Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci U S A (1991) 3.34
Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 component of the cap-binding protein complex. J Virol (1988) 3.28
A generic intron increases gene expression in transgenic mice. Mol Cell Biol (1991) 2.75
Foot-and-mouth disease. Annu Rev Microbiol (1968) 2.70
Protein N-myristoylation in Escherichia coli: reconstitution of a eukaryotic protein modification in bacteria. Proc Natl Acad Sci U S A (1990) 2.61
Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination. J Virol (1987) 2.02
Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol (1996) 1.80
Protective immune response against foot-and-mouth disease. J Virol (1992) 1.77
Proteolytic processing of foot-and-mouth disease virus polyproteins expressed in a cell-free system from clone-derived transcripts. J Virol (1987) 1.77
Myristoylation of the poliovirus polyprotein is required for proteolytic processing of the capsid and for viral infectivity. J Virol (1990) 1.72
New approaches to vaccination against foot-and-mouth disease. Vaccine (1992) 1.68
Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. J Virol (1989) 1.59
Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature (1987) 1.57
Biochemical identification of viruses causing the 1981 outbreaks of foot and mouth disease in the UK. Nature (1981) 1.39
A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle. J Immunol (1991) 1.31
A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus. J Gen Virol (1975) 1.27
Host cell selection of antigenic variants of foot-and-mouth disease virus. J Gen Virol (1989) 1.26
Synthesis of foot-and-mouth disease virus capsid proteins in insect cells using baculovirus expression vectors. J Gen Virol (1990) 1.23
Isotype responses of infected, virus-vaccinated and peptide-vaccinated cattle to foot-and-mouth disease virus. Vaccine (1990) 1.19
Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J Gen Virol (1995) 1.11
Identification of native foot-and-mouth disease virus non-structural protein 2C as a serological indicator to differentiate infected from vaccinated livestock. Res Vet Sci (1995) 1.10
Stability and immunogenicity of empty particles of foot-and-mouth disease virus. Arch Virol (1979) 1.07
Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12. Virus Res (1984) 1.05
Identification of foot-and-mouth disease virus replication in vaccinated cattle by antibodies to non-structural virus proteins. Vaccine (1990) 1.04
Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol (1991) 1.04
Characterization of synthetic foot-and-mouth disease virus provirions separates acid-mediated disassembly from infectivity. J Virol (1997) 1.01
T cell-dependent induction of antibody against foot-and-mouth disease virus in a mouse model. J Gen Virol (1989) 1.01
Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. J Virol (1997) 1.00
Identification of the active-site residues of the 3C proteinase of foot-and-mouth disease virus. Virology (1995) 1.00
Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells. J Virol (1985) 0.96
Comparative immunogenicity of 146S, 75S and 12S particles of foot-and-mouth disease virus. Arch Virol (1982) 0.87
Protection of swine against foot-and-mouth disease with viral capsid proteins expressed in heterologous systems. Vaccine (1993) 0.85
Comparison of capsid protein VP1 of the viruses used for the production and challenge of foot-and-mouth disease vaccines in Spain. Vaccine (1992) 0.79
The immune response against foot-and-mouth disease virus: influence of the T lymphocyte growth factors IL-1 and IL-2 on the murine humoral response in vivo. Immunol Lett (1992) 0.79
Role for DNA methylation in genomic imprinting. Nature (1993) 12.65
A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity (2001) 9.45
Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet (2001) 6.92
Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science (1981) 5.66
Implementing a 48 h EWTD-compliant rota for junior doctors in the UK does not compromise patients' safety: assessor-blind pilot comparison. QJM (2009) 4.23
DNA hypomethylation leads to elevated mutation rates. Nature (1998) 3.60
Germ-line passage is required for establishment of methylation and expression patterns of imprinted but not of nonimprinted genes. Genes Dev (1996) 3.29
Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 component of the cap-binding protein complex. J Virol (1988) 3.28
DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. J Neurosci (2001) 2.75
Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol (1995) 2.66
Nucleotide and amino acid sequence coding for polypeptides of foot-and-mouth disease virus type A12. J Virol (1985) 2.65
Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol (1997) 2.51
Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol (1993) 2.50
Relationship of p220 cleavage during picornavirus infection to 2A proteinase sequencing. J Virol (1988) 2.32
Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15
Treatment for displaced intracapsular fracture of the proximal femur. A prospective, randomised trial in patients aged 65 to 79 years. J Bone Joint Surg Br (2001) 2.11
The importance of inorganic phosphate in regulation of energy metabolism of Streptococcus lactis. J Biol Chem (1981) 2.05
Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J Virol (1993) 1.97
Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol (1999) 1.94
Part-time women general practitioners--workload and remuneration. J R Coll Gen Pract (1989) 1.92
Sub-cellular localization of vesicular stomatitis virus messenger RNAs. Biochem Biophys Res Commun (1975) 1.91
In vitro synthesis of proteins by membrane-bound polyribosomes from vesicular stomatitis virus-infected HeLa cells. J Virol (1974) 1.90
Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. J Virol (1998) 1.83
Proteolytic processing of foot-and-mouth disease virus polyproteins expressed in a cell-free system from clone-derived transcripts. J Virol (1987) 1.77
Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76
Isolation and characterization of the SPT2 gene, a negative regulator of Ty-controlled yeast gene expression. Mol Cell Biol (1985) 1.62
The foot-and-mouth disease virus leader proteinase gene is not required for viral replication. J Virol (1995) 1.61
Experimental and clinical data on the insertion of the levator palpebrae superioris muscle. Am J Ophthalmol (1978) 1.57
Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology (1991) 1.55
RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys (1995) 1.52
Identification of amino acid and nucleotide sequence of the foot-and-mouth disease virus RNA polymerase. Virology (1983) 1.51
The levator aponeurosis. Attachments and their clinical significance. Arch Ophthalmol (1977) 1.49
Mutations in the WRN gene in mice accelerate mortality in a p53-null background. Mol Cell Biol (2000) 1.48
Biochemical map of polypeptides specified by foot-and-mouth disease virus. J Virol (1984) 1.46
Germ line transmission of a yeast artificial chromosome spanning the murine alpha 1(I) collagen locus. Science (1993) 1.45
Genetic determinants of altered virulence of Taiwanese foot-and-mouth disease virus. J Virol (2000) 1.44
Translation of foot-and-mouth disease virion RNA and processing of the primary cleavage products in a rabbit reticulocyte lysate. Virology (1982) 1.44
A recency-based account of the primacy effect in free recall. J Exp Psychol Learn Mem Cogn (2000) 1.43
Ability of foot-and-mouth disease virus to form plaques in cell culture is associated with suppression of alpha/beta interferon. J Virol (1999) 1.43
Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine (1994) 1.43
Identification of the active-site residues of the L proteinase of foot-and-mouth disease virus. J Virol (1995) 1.42
DNA methylation, genomic imprinting, and mammalian development. Cold Spring Harb Symp Quant Biol (1993) 1.41
Partial nucleotide sequence of the Japanese encephalitis virus genome. Virology (1987) 1.39
In vitro protein-synthesizing activity of vesicular stomatitis virus-infected cell extracts. J Virol (1973) 1.37
Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in cattle. J Virol (1996) 1.35
In vitro identification of a B19 parvovirus promoter. Virology (1987) 1.35
Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J Virol (2001) 1.33
Antiviral effects of a thiol protease inhibitor on foot-and-mouth disease virus. J Virol (1992) 1.29
Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology (1995) 1.29
Inhibition of L-deleted foot-and-mouth disease virus replication by alpha/beta interferon involves double-stranded RNA-dependent protein kinase. J Virol (2001) 1.28
Foot-and-mouth disease virion RNA: studies on the relation between the length of its 3'-poly(A) segment and infectivity. Virology (1979) 1.25
Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology (1997) 1.24
A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology (1992) 1.24
Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J Virol (1998) 1.23
Receptor binding site-deleted foot-and-mouth disease (FMD) virus protects cattle from FMD. J Virol (1995) 1.23
Studies on the in vivo and in vitro messenger RNA species of vesicular stomatitis virus. Virology (1975) 1.23
Sindbis vectors suppress secretion of subviral particles of Japanese encephalitis virus from mammalian cells infected with SIN-JEV recombinants. Virology (1995) 1.21
Longitudinal study of bone turnover after acute spinal cord injury. J Clin Endocrinol Metab (1998) 1.21
Animal-derived antigenic variants of foot-and-mouth disease virus type A12 have low affinity for cells in culture. J Virol (1994) 1.21
The structural polypeptides of aphthovirus are phosphoproteins. Proc Natl Acad Sci U S A (1980) 1.20
Sequence variation in the gene for the immunogenic capsid protein VP1 of foot-and-mouth disease virus type A. Proc Natl Acad Sci U S A (1985) 1.19
Subcellular distribution of the foot-and-mouth disease virus 3A protein in cells infected with viruses encoding wild-type and bovine-attenuated forms of 3A. Virology (2001) 1.19
Evaluation of 48 cases of orbital exenteration. Am J Ophthalmol (1971) 1.18
Isolation of foot-and-mouth disease virus messenger RNA from membrane-bound polyribosomes and characterization of its 5' and 3' termini. Virology (1979) 1.16
Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus. Vaccine (1998) 1.16
Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine (2000) 1.15
The pathogenesis of foot-and-mouth disease II: viral pathways in swine, small ruminants, and wildlife; myotropism, chronic syndromes, and molecular virus-host interactions. Transbound Emerg Dis (2011) 1.15
Cryotherapy of basal cell carcinoma in oculoplastic surgery. Am J Ophthalmol (1976) 1.14
Blepharochalasis. Br J Ophthalmol (1979) 1.14
The surgical treatment of blepharoptosis: a quantitative approach. Trans Am Ophthalmol Soc (1966) 1.13
A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine (2000) 1.12
National Quality Measures for Breast Centers (NQMBC): a robust quality tool: breast center quality measures. Ann Surg Oncol (2009) 1.12
Emergence in Asia of foot-and-mouth disease viruses with altered host range: characterization of alterations in the 3A protein. J Virol (2001) 1.12
Mitogenicity of DNA from different organisms for murine B cells. J Immunol (1997) 1.11
Cryosurgery for treatment of trichiasis. Am J Ophthalmol (1976) 1.11
Lower eyelid reconstruction by tarsal transposition. Am J Ophthalmol (1976) 1.10
Analysis of splice junctions and in vitro and in vivo translation potential of the small, abundant B19 parvovirus RNAs. Virology (1991) 1.10
Expression of Japanese encephalitis virus antigens in Escherichia coli. Virology (1987) 1.08
Transformation of an insect symbiont and expression of a foreign gene in the Chagas' disease vector Rhodnius prolixus. Am J Trop Med Hyg (1992) 1.08
Identification and characterization of messenger ribonucleoprotein complexes from vesicular stomatitis virus-infected HeLa cells. Virology (1977) 1.08
Observations on the treatment of basal cell carcinoma of the eyelids. The Wendell L. Huges Lecture. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol (1976) 1.08
Spinal anaesthesia for Caesarean section in a patient with systemic sclerosis. Anaesthesia (1999) 1.08
Surgical removal of basal cell carcinoma of the eyelids utilizing frozen section control. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol (1976) 1.06
Studies of genetically defined chimeras of a European type A virus and a South African Territories type 2 virus reveal growth determinants for foot-and-mouth disease virus. J Gen Virol (2004) 1.05
Hormonal effects of norepinephrine on acute glucose disposal in humans: a minimal model analysis. Metabolism (1988) 1.04
Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol (1991) 1.04
Foot-and-mouth disease virus undergoes restricted replication in macrophage cell cultures following Fc receptor-mediated adsorption. Virology (1995) 1.03
Recombinant swine beta interferon protects swine alveolar macrophages and MARC-145 cells from infection with Porcine reproductive and respiratory syndrome virus. J Gen Virol (2007) 1.02
A miniature infuser for the pulsatile administration of LHRH. J Biomed Eng (1984) 1.02
Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV. J Virol (1994) 1.02
Characterization of synthetic foot-and-mouth disease virus provirions separates acid-mediated disassembly from infectivity. J Virol (1997) 1.01
Essential fatty acid uptake and metabolism in the developing rodent brain. Lipids (1996) 1.00